Granules India has that it enclosed press release today titled ‘Granules Pharmaceuticals, Inc. Successfully Completes USFDA Postmarketing Adverse Drug Experience (PADE) Inspection with Zero Observations’.
The above information is a part of company’s filings submitted to BSE.